PriceTargets.com logo

Onconova Therapeutics - ONTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 693.65 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.26 As of 08/18/2022 01:00 AM ET
▼ -0.01 (-0.79%)

This chart shows the closing price for ONTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Onconova Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONTX

Analyst Price Target is $10.00
▲ +693.65% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Onconova Therapeutics in the last 3 months. The average price target is $10.00, with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 693.65% upside from the last price of $1.26.

This chart shows the closing price for ONTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Onconova Therapeutics. This rating has held steady since August 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/20/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/20/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/12/2022Noble FinancialReiterated RatingBuy$11.00High
3/1/2022LADENBURG THALM/SH SHInitiated CoverageBuy$7.00High
9/28/2021GuggenheimLower TargetBuy$29.00 ➝ $12.00Low
9/23/2021Noble FinancialReiterated RatingBuy$11.00Low
6/29/2021Noble FinancialReiterated RatingBuy$11.00Low
5/18/2021GuggenheimInitiated CoverageBuy$4.00High
12/22/2020Noble FinancialUpgradeMarket Perform ➝ OutperformLow
11/13/2020Maxim GroupReiterated RatingHoldMedium
8/25/2020Noble FinancialDowngradeOutperform ➝ Market PerformLow
8/24/2020LaidlawDowngradeBuy ➝ HoldHigh
8/24/2020Maxim GroupDowngradeBuy ➝ HoldHigh
8/24/2020HC WainwrightDowngradeBuy ➝ NeutralN/A
8/13/2020Noble FinancialReiterated RatingBuy$19.50High
8/3/2020Noble FinancialReiterated RatingBuyLow
7/27/2020HC WainwrightReiterated RatingBuy$30.00Medium
6/23/2020Maxim GroupInitiated CoverageBuy$18.75Medium
6/15/2020Noble FinancialReiterated RatingBuy$19.50Medium
5/15/2020Maxim GroupUpgradeHold ➝ Buy$18.75High
3/25/2020HC WainwrightReiterated RatingBuyHigh
12/27/2019Noble FinancialReiterated RatingBuy$19.50High
11/26/2019Maxim GroupDowngradeBuy ➝ HoldHigh
10/29/2019Noble FinancialReiterated RatingBuy$180.00High
9/9/2019Maxim GroupSet TargetBuy$120.00Low
8/12/2019Maxim GroupSet TargetBuy$120.00Medium
7/25/2019Noble FinancialInitiated CoverageOutperform$180.00High
5/14/2019HC WainwrightSet TargetBuy$375.00Medium
5/14/2019Maxim GroupReiterated RatingBuy$240.00High
3/26/2019HC WainwrightSet TargetBuy$375.00High
3/25/2019Maxim GroupReiterated RatingBuy$240.00Low
2/8/2019HC WainwrightReiterated RatingBuy$375.00Low
12/3/2018HC WainwrightSet TargetBuy$375.00High
12/3/2018Maxim GroupSet TargetBuy$240.00High
11/14/2018HC WainwrightSet TargetBuy$375.00High
11/13/2018Maxim GroupSet TargetBuy$240.00High
10/11/2018Maxim GroupLower TargetBuy$675.00 ➝ $240.00Medium
9/27/2018HC WainwrightReiterated RatingBuy$375.00Medium
8/14/2018HC WainwrightSet TargetBuy$675.00High
8/14/2018Maxim GroupReiterated RatingBuy$675.00High
5/15/2018HC WainwrightSet TargetBuy$675.00High
5/2/2018Maxim GroupUpgradeHold ➝ BuyMedium
3/26/2018HC WainwrightSet TargetBuy$1,800.00Low
3/26/2018Maxim GroupReiterated RatingHoldLow
3/9/2018HC WainwrightReiterated RatingBuy$1,800.00Low
3/8/2018Maxim GroupReiterated RatingHoldLow
3/2/2018Maxim GroupReiterated RatingHoldMedium
3/1/2018HC WainwrightReiterated RatingBuy ➝ Buy$1,350.00 ➝ $1,687.50Low
1/18/2018HC WainwrightReiterated RatingBuy$1,350.00High
1/17/2018Maxim GroupDowngradeBuy ➝ HoldHigh
1/4/2018HC WainwrightSet TargetBuy$1,350.00High
12/19/2017HC WainwrightSet TargetBuy$1,350.00High
12/12/2017HC WainwrightSet TargetBuy$1,350.00Medium
11/9/2017HC WainwrightReiterated RatingBuyN/A
11/9/2017Maxim GroupSet TargetBuy$1,350.00N/A
11/2/2017Maxim GroupReiterated RatingBuy$1,350.00N/A
10/9/2017HC WainwrightInitiated CoverageBuy ➝ Buy$1,350.00N/A
(Data available from 8/19/2017 forward)

News Sentiment Rating

-0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/22/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/21/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/19/2022

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Onconova Therapeutics logo
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Read More

Today's Range

Now: $1.26
Low: $1.24
High: $1.27

50 Day Range

MA: $1.27
Low: $1.15
High: $1.45

52 Week Range

Now: $1.26
Low: $1.00
High: $6.77

Volume

91,465 shs

Average Volume

144,812 shs

Market Capitalization

$26.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Onconova Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Onconova Therapeutics in the last twelve months: Guggenheim, LADENBURG THALM/SH SH, Noble Financial, and StockNews.com.
View the latest analyst ratings for ONTX.

What is the current price target for Onconova Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Onconova Therapeutics in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 693.7%. Guggenheim has the highest price target set, predicting ONTX will reach $12.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $7.00 for Onconova Therapeutics in the next year.
View the latest price targets for ONTX.

What is the current consensus analyst rating for Onconova Therapeutics?

Onconova Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ONTX will outperform the market and that investors should add to their positions of Onconova Therapeutics.
View the latest ratings for ONTX.

What other companies compete with Onconova Therapeutics?

Other companies that are similar to Onconova Therapeutics include Tempest Therapeutics, Forward Pharma A/S, Corbus Pharmaceuticals, NeuBase Therapeutics and Aravive. Learn More about companies similar to Onconova Therapeutics.

How do I contact Onconova Therapeutics' investor relations team?

Onconova Therapeutics' physical mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company's listed phone number is (267) 759-3680 and its investor relations email address is [email protected] The official website for Onconova Therapeutics is www.onconova.com. Learn More about contacing Onconova Therapeutics investor relations.